An Executive Informational Overview (EIO) is now available on a revenue-generating Canadian biotechnology company, Ceapro Inc. (CZO-TSX.V). The EIO is a 64-page report detailing Ceapro's business, products and pipeline, strategic relationships, market opportunities, competition, financials, risks, and more. It is available for download below.
/Ceapro_EIO_Cover.jpg?width=241&name=Ceapro_EIO_Cover.jpg "Ceapro_EIO_Cover.jpg") |
 |
Snapshot of Ceapro
Ceapro (or “the Company”) is involved in the production and commercialization of botanically derived, biologically active compounds—termed bioactives—for human and animal healthcare markets. The Company’s product portfolio is largely based on two oat compounds: beta glucan (β-glucan) and avenanthramides. To date, Ceapro’s bioactives have been used as ingredients in multiple household products in the personal care and cosmetics industries, including in products from Aveeno®, Burt’s Bees®, Nexxus®, RoC®, and Neutrogena®. Ceapro also markets veterinary therapeutic products in Asia through agreements with Daisen Sangyo Co. Ltd.
Going forward, the Company plans to leverage its proprietary manufacturing processes and technology platform—Pressurized Gas eXpanded Liquid Technology (PGX)—into its own product pipeline for the nutraceutical and pharmaceutical markets. This work, which augments Ceapro’s profitable cosmeceutical operations, seeks to capitalize on the therapeutic properties of β-glucan and avenanthramides for a cholesterol reducer, a functional drink, and the treatment of exercise-induced inflammation, among other areas. On September 28, 2016, Ceapro announced the opening of a new, 30,000 sq. ft. manufacturing and research facility in Edmonton, and expects to complete the transfer of all manufacturing operations by the first quarter 2017.
5 Key Points of Ceapro's Business
Ceapro holds competitive advantages in the cosmeceutical, nutraceutical, and pharmaceutical markets. Visit our full Key Points page on Ceapro to learn more about the Company's investment highlights.
-
Ceapro reported record financial performance in 2015, with revenues of C$10.7 million (+20% vs. 2014) and income from operations of C$3.6 million (+81.5% vs. 2014). This was followed by record first and second quarters in 2016, resulting in cumulative revenues of C$8.2 million (+98% over the first six months of 2015) and cumulative income from operations of C$4.4 million vs. C$0.6 million for the first six months of 2015.
-
According to Ceapro, its financial performance is a direct result of a three-year focus on maximizing revenues, maintaining favorable profit margins through manufacturing efficiencies and low overhead, and securing multiple research grants and financial contributions through partnerships.
-
The Company is working to advance both its nutraceutical and pharmaceutical development projects into the clinical stage, which includes initiating a pilot study and a safety study to develop β-glucan as a cholesterol reducer during 2016.
-
The Company believes that its revenue-generating cosmeceutical business in conjunction with its value-driven expansion into nutraceuticals and pharmaceuticals provides a low-risk model.
-
As of June 30, 2016, Ceapro reported C$0.9 million in cash and cash equivalents. The Company subsequently closed a private placement for gross proceeds of C$10 million in July 2016.
*******************************************
Visit our Corporate Profile and Key Points pages
for the latest research on Ceapro Inc.
*******************************************